Channel Therapeutics Corporation (formerly Chromocell Therapeutics)

Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The company’s clinical focus is on selectively targeting the sodium ion-channel known as NaV1.7, which has been genetically validated as a pain receptor in human physiology. Their proprietary molecule, CC8464, is being developed to address neuropathic pain by restricting its entry into the central nervous system, thereby reducing the risk of addiction and other adverse effects. Additionally, the company is advancing CT2000 for the treatment of acute and chronic eye pain, offering a safer and more effective alternative to existing therapies. Channel Therapeutics is committed to innovation in pain management and improving patient outcomes.